Advanced Filters
noise

Down's Syndrome Clinical Trials

A listing of Down's Syndrome medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 27 clinical trials

Outcomes Mandate National Integration With Cannabis as Medicine

This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.

7 - 100 years of age Both Phase 2
H Haley Obolewicz, RN

Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement

Hypothesis: Improvement in cognitive dysfunction with IV albumin in patients with cirrhosis with prior HE and MHE lasts for several weeks after albumin infusion has ended, and is due to persistent improvement in inflammatory markers, endothelial dysfunction, albumin function and gut microbial changes. This will be a single-arm, single-blind sequential …

18 - 100 years of age Both Phase 2
C Clinical Research Coordinator

Deprescribing Proton Pump Inhibitors to Reduce Post-TIPS Hepatic Encephalopathy

A total of 40 patients taking proton pump inhibitors (PPIs) who undergo transjugular intrahepatic portosystemic shunt (TIPS) creation as part of routine clinical care will be randomized in 1:1 fashion to either continue or discontinue their PPIs to determine whether these commonly used gastric acid suppressing agents increase risk of …

18 - 100 years of age Both Phase 1/2
C Christophe BUREAU, PH

Hepatic Encephalopathy Prevention With Polydextrose After TIPS: Pilot Study (POEME)

TIPS is a standard for the treatment of portal hypertension related complications. However, it remains at risk of HE after TIPS (around 40% the first year). Dysbiosis plays a key role in pathophysiology of HE. Polydextrose (PDX) is consider as a prebiotic. Preliminary studies showed that PDX: modified gut microbiota, …

18 - 70 years of age Both Phase N/A
F Francesca Ponziani, MD

Fecal Microbiota Transplantation by Oral Capsules for Hepatic Encephalopathy Treatment

This interventional study aims to evaluate the safety and efficacy of oral capsule fecal microbiota transplantation (FMT) for treating hepatic encephalopathy refractory to conventional rifaximin and lactulose therapy in patients with liver cirrhosis. Patients diagnosed with hepatic encephalopathy refractory to rifaximin and lactulose therapy will be randomized into three groups. …

18 - 80 years of age Both Phase 1

Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy

Efficacy and Safety of Nitazoxanide in preventing recurrence of Hepatic Encephalopathy.

20 - 65 years of age Both Phase 3
R Revathi Penumatsa

Late Evening and Early Morning Protein Supplement to Reduce Readmissions for Hepatic Encephalopathy

Readmission rates for patients with hepatic encephalopathy due to end stage liver disease are high. Hyperammonemia contributes significantly to encephalopathy and occurs because of impaired hepatic ureagenesis and increased skeletal muscle proteolysis. We propose a randomized, 6-month nutritional intervention in cirrhotic patients who have had at least 1 admission for …

18 - 75 years of age Both Phase N/A

Comparing Nifuroxazide Plus Lactulose With Lactulose Alone in the Treatment of Hepatic Encephalopathy

Evaluating the efficacy and safety of the efficacy and safety of nifuroxazide in combination with lactulose in comparison to lactulose alone in the treatment of hepatic encephalopathy in patients with grade II-III hepatic encephalopathy

18 - 100 years of age Both Phase 3
C CHIEN-HUNG CHEN, MD

Microbiota, Sarcopenia, and Hepatic Encephalopathy Change in Cirrhotic Patients Before and After Rehabilitation

Through this plan, it will provide many benefits to patients with liver cirrhosis complicated with sarcopenia and/or hepatic encephalopathy, their family members, and the government in Taiwan To explore the changes of fecal microbiota before and after treatment such as resistance training rehabilitation in patients with liver cirrhosis complicated with …

20 - 100 years of age Both Phase N/A

Role of Sarcopenia and Nutritional/Physical Therapy Intervention in Post-TIPS Hepatic Encephalopathy

The placement of TIPS (transjugular intrahepatic portosystemic shunt) is the most effective strategy to treat complications of portal hypertension. However, the threat of developing post-TIPS complications diminishes its use and applicability. Hepatic encephalopathy (HE) is the most feared and frequent post-TIPS complication, affecting between 25-54% of patients. Available treatments against …

18 - 100 years of age Both Phase N/A

Rewrite in simple language using AI